Gold Sponsors
AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide. We operate in over 100 countries and work on the discovery, development and commercialisation of prescription medicines. Our focus areas include Cardiovascular, Renal and Metabolism (CVRM), Oncology and Respiratory.
- www.astrazeneca.com
- Booth: B02
MSD
For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for the world's most challenging diseases. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola.
- www.msd.com
- Booth: A02
Pfizer Oncology
At Pfizer Singapore, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care in Singapore.
- www.pfizer.com.sg
- Booth: B01
Silver Sponsors
Ipsen
Ipsen (Euronext: IPN; ADR: IPSEY) is a global biopharmaceutical group focused on innovation and specialty care. Oncology is one of Ipsen’s focused therapeutic areas with a solid portfolio of innovative medicines. Ipsen focuses its efforts in fighting cancers such as prostate cancer, bladder cancer, neuroendocrine tumors, kidney cancer, breast cancer and other niche oncology diseases.
- www.ipsen.com
- Booth: B03
Merck
Merck is a leading science and technology company in healthcare, life science and performance materials, developing technologies improving life, biopharmaceutical therapies treating cancer or multiple sclerosis, helping patients with infertility, endocrine and metabolic disorders or cardiovascular diseases, cutting-edge systems for scientific research and production. Merck holds the global rights to the Merck name and brand. Exceptions: US and Canada, where the company operates as EMD Serono, MilliporeSigma, EMD Performance Materials, MilliporeSigma and EMD Performance Materials.
- www.merck.com
- Booth: C01
Roche
Since 1896, Roche has been a global pioneer in advancing science to improve people’s lives. Today we are leaders in truly differentiated medicines (in oncology, immunology and more) and diagnostics (in vitro diagnostics, tissue-based cancer diagnostics and more). We also lead and partner in personalised healthcare – a strategy to identify the right treatment for the right patient at the right time.
- www.roche.com
- Booth: C02
Bronze Sponsors
Astellas Pharma Singapore Pte. Ltd.
Astellas is a Tokyo based pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals.
- www.astellas.com
- Booth: D01
Bristol-Myers Squibb
Bristol-Myers Squibb (Headquarters: New York, CEO: Giovanni Caforio) is a global specialty biopharmaceutical company with more than 130 years of history, operating worldwide. With the mission to discover, develop and deliver innovative medicines that help patients prevail over serious diseases, the company concentrates its R&D efforts on four key disease areas, “Oncology”, “Immunoscience”, “Cardiovascular” and “Fibrosis”.
- www.bms.com
- Booth: Not Applicable
Eisai
Eisai Co., Ltd. is a global pharmaceutical company headquartered in Tokyo, Japan. Eisai has about 60 years of history in Asia, and continues to explore new ways to realize its corporate mission of “giving first thoughts to patients and their families and to increasing the benefits health care provides”, i.e. the “human health care (hhc)” philosophy. In alignment with this, Eisai Asia Region is devoted to continuously improve access to Eisai’s innovative cancer drugs through innovative access programs and science-based activities across Asia.
- www.eisai.com
- Booth: D02
Lilly Oncology
For more than fifty years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world.
- www.lillyoncology.com
- Booth: E01
Takeda Pharmaceuticals
Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and neuroscience therapeutic areas, plus vaccines. Approximately 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda’s partners in health care in more than 70 countries.
- www.takeda.com
- Booth: A03
Exhibitors
Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
- www.amgen.com
- Booth: D03
Beacon Medicare Limited
BEACON Medicare Limited is a concern of BEACON Group and Global Marketing Partner of BEACON Oncology Limited. BEACON is the Number 1 Oncology company and one of the leading pharma companies of Bangladesh. The company has started its business operation in 2006 with a vision of caring global patient. BEACON manufactures more than 100 lifesaving anti-cancer products. Besides the conventional chemotherapy products, BEACON manufactures MABs, Targeted therapies, Nano and Lyposomal preparations. After meeting the local demand, BEACON exports its medicines globally. Patients of 120 countries including USA, Europe, and Australia are using BEACON’s medicines.
- www.beaconmedicare.com.bd
- Booth: B14
Biocartis
Biocartis aims to provide direct access to personalized medicine for patients worldwide by developing fully integrated, broadly applicable molecular diagnostics. Biocartis’ MDx Idylla™ platform is a fully automated sample-to-result, real-time Polymerase Chain Reaction system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting.
- www.biocartis.com
- Booth: A24
Boehringer-Ingelheim Singapore Pte. Ltd.
Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas; human pharmaceuticals, animal health and biopharmaceuticals. In 2017, Boehringer Ingelheim achieved net sales of nearly 18.1 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 17.0 percent of net sales.
- www.boehringer-ingelheim.com
- Booth: A04
ECS-Screening
ECS-Screening is a Swiss company that has pioneered the development of two unique laboratory tests for the detection of circulating progastrin. The presence of progastrin in the blood is linked to the presence of tumor cells. CancerREAD Smart helps health care providers screen patients for many cancer types, such as breast and colorectal cancers, even in their early stages. CancerREAD Lab helps doctors monitor how their patients’ cancers respond to therapy.
- www.ecs-screening.ch
- Booth: E02
Guardant Health
Guardant Health is a leading precision oncology company helping conquer cancer globally through proprietary blood tests, vast data sets and advanced analytics. Our oncology platform leverages capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs.
- www.guardanthealth.com
- Booth: E04
HalioDx
HalioDx is an immuno-oncology diagnostic company providing oncologists with first-in-class diagnostic products and services to guide cancer care and contribute to precision medicine. Immunoscore®, reflecting the immune response to tumor, is a key hallmark of disease progression and a powerful prognostic assay, already available for colon cancer. HalioDx proposes also assays for clinical research, notably to stratify patients for immunotherapies.
- www.haliodx.com
- Booth: B04
Lucence Diagnostics
Lucence Diagnostics is a genomic medicine company focused on inventing advanced cancer diagnostics to improve cancer care. Headquartered in Singapore with offices in Hong Kong and the US, Lucence invents genetic tests that enable earlier cancer diagnosis and better treatment selections. Lucence’s tests target the most common cancers in the world based on its patented sequencing technology and in-house clinical analytics.
- www.lucencedx.com
- Booth: E05
Merck Pfizer Alliance
Immuno-oncology is a top priority for Merck and Pfizer. The alliance between Merck and Pfizer enables the companies to benefit from each other’s strengths and capabilities and further explore the therapeutic potential of avelumab, an anti-PD-L1 antibody initially discovered and developed by Merck. The alliance will jointly develop and commercialize avelumab and is striving to find new ways to treat cancer.
- www.merckgroup.com
- Booth: F01
NanoString Technologies
NanoString is a life sciences company focused on cancer research and diagnostics. Proven in over 1,000 peer-reviewed publications, the nCounter® System can combine with 3D biology™ technology to create novel biomarkers. The Prosigna® Breast Cancer Prognostic Gene Signature Assay provides FDA 510(k)-cleared diagnostics with the nCounter Dx Analysis System.
- www.nanostring.com
- Booth: B25
Tessa Therapeutics Pte Ltd.
Tessa Therapeutics is a clinical stage biopharmaceutical company with the scientific vision to revolutionize cancer treatment by redirecting the body’s anti-viral immune response to recognize and kill cancer cells. Today, we are a leader in Virus-Specific T cell therapy and are conducting the world’s first FDA Phase III T cell therapy trial in a solid tumour indication.
- www.tessatherapeutics.com
- Booth: F02
Thermo Fisher Scientific
At Thermo Fisher Scientific, everything we do begins with our Mission - to enable our customers to make the world healthier, cleaner and safer. To fulfill our Mission, we have a remarkable team of colleagues who bring unique perspectives and talents. Their dedication leads to innovative technologies that help our customers address some of society's most pressing challenges, including treatment of disease, access to clean water and ensuring the safety of our communities.
- www.thermofisher.com
- Booth: E03
Educational Grant Sponsors
Bristol-Myers Squibb
Bristol-Myers Squibb (Headquarters: New York, CEO: Giovanni Caforio) is a global specialty biopharmaceutical company with more than 130 years of history, operating worldwide. With the mission to discover, develop and deliver innovative medicines that help patients prevail over serious diseases, the company concentrates its R&D efforts on four key disease areas, “Oncology”, “Immunoscience”, “Cardiovascular” and “Fibrosis”.
Helsinn Healthcare SA
Founded in 1976, Helsinn Healthcare SA is a privately owned Swiss pharmaceutical group with 650 employees with headquarter in Switzerland and subsidiaries in Ireland, USA and China.
The Group focuses on cancer care and therapeutic niche areas by in-licensing early to late stage new products and utilizing its capabilities to complete development, marketing approval, commercialization.
Helsinn’s products are commercialized in 190 countries through 70 selected partners.